Lieming Ding
Impact in
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Pharmacology top 10%
Papers in
-
- Lung Cancer Treatments and Mutations 33
- Renal cell carcinoma treatment 2
-
- Analytical Methods in Pharmaceuticals 3
- Co-authors
- Fenlai Tan (12 shared papers)Guojian Xie (2 shared papers)Yanping Wang (3 shared papers)Xiaobin Yuan (7 shared papers)Xiaoyan Shen (1 shared paper)Shun Lü (2 shared papers)Yinxiang Wang (3 shared papers)Yuankai Shi (3 shared papers)
- Journals
- Lung Cancer (4 papers)The Lancet Respiratory Medicine (3 papers)Journal of Thoracic Oncology (3 papers)Frontiers in Oncology (2 papers)The Oncologist (2 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Lieming Ding
51 papers receiving 1.4k citations
Lieming Ding's Hit Papers
Peers
Comparison fields: 5 of 57
- Pulmonary and Respiratory Medicine 964
- Pharmacology 43
- Oncology 98
- Organic Chemistry 94
- Cancer Research 35
Countries citing papers authored by Lieming Ding
This map shows the geographic impact of Lieming Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lieming Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lieming Ding more than expected).
Fields of papers citing papers by Lieming Ding
This network shows the impact of papers produced by Lieming Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lieming Ding. The network helps show where Lieming Ding may publish in the future.
Co-authors
The 25 scholars most cited alongside Lieming Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Hit paper breakdown → | 2013 | 377 |
| 2 | 2021 | 136 | |
| 3 | 2011 | 124 | |
| 4 | 2019 | 114 | |
| 5 | 2023 | 55 | |
| 6 | 2012 | 54 | |
| 7 | 2016 | 48 | |
| 8 | 2014 | 43 | |
| 9 | 2015 | 39 | |
| 10 | 2018 | 31 | |
| 11 | 2021 | 31 | |
| 12 | 2016 | 30 | |
| 13 | 2022 | 23 | |
| 14 | 2021 | 21 | |
| 15 | 2022 | 20 | |
| 16 | 2020 | 19 | |
| 17 | 2023 | 19 | |
| 18 | 2020 | 18 | |
| 19 | 2002 | 16 | |
| 20 | 2021 | 15 |
About Lieming Ding
Lieming Ding is a scholar working on Pulmonary and Respiratory Medicine, Analytical Chemistry, Radiology, Nuclear Medicine and Imaging, Cancer Research and Oncology, having authored 53 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (33 papers), Analytical Methods in Pharmaceuticals (3 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers), Angiogenesis and VEGF in Cancer (2 papers), Renal cell carcinoma treatment (2 papers), Radiomics and Machine Learning in Medical Imaging (2 papers), Statistical Methods in Clinical Trials (1 paper) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (964 citations), Pharmacology (43 citations), Oncology (98 citations), Organic Chemistry (94 citations) and Cancer Research (35 citations). Lieming Ding has collaborated with scholars based in China and United States. Frequent co-authors include Fenlai Tan, Guojian Xie, Yanping Wang, Xiaobin Yuan, Xiaoyan Shen, Shun Lü, Yinxiang Wang, Yuankai Shi, Bin Yan Wu and Jie Fu. Their work appears in journals such as Lung Cancer, The Lancet Respiratory Medicine, Journal of Thoracic Oncology, Frontiers in Oncology and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.